216 related articles for article (PubMed ID: 17690487)
1. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
[TBL] [Abstract][Full Text] [Related]
2. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
Akinci B; Demir T; Comlekci A; Yener S; Ozcan MA; Karaoglu O; Yuksel F; Secil M; Yesil S
Med Princ Pract; 2011; 20(1):23-8. PubMed ID: 21160209
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
5. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
Akinci B; Comlekci A; Ali Ozcan M; Demir T; Yener S; Demirkan F; Yuksel F; Yesil S
Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
[TBL] [Abstract][Full Text] [Related]
6. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
7. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
8. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
9. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
Liu YF; Hou N; Shi YJ; Li CX; Gao YJ; Liu LN
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1638-1642. PubMed ID: 37248064
[No Abstract] [Full Text] [Related]
11. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
12. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu İ; Ersoz HO
Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
[TBL] [Abstract][Full Text] [Related]
13. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Bollen L; Peetermans M; Peeters M; Van Steen K; Hoylaerts MF; Declerck PJ; Verhamme P; Gils A
Thromb Res; 2014 Nov; 134(5):1097-102. PubMed ID: 25193405
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
[TBL] [Abstract][Full Text] [Related]
16. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
Watanabe R; Wada H; Watanabe Y; Sakakura M; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Nobori T; Shiku H
Thromb Res; 2001 Oct; 104(1):1-6. PubMed ID: 11583733
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolysis parameters in Sudanese women with severe preeclampsia.
Elzein HO; Muddathir AR; Rida M; Rayis DA; Elhassan EM; Adam I
Hypertens Pregnancy; 2016 Nov; 35(4):559-564. PubMed ID: 27598010
[TBL] [Abstract][Full Text] [Related]
18. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
Akinci B; Demir T; Saygili S; Yener S; Alacacioglu I; Saygili F; Bayraktar F; Yesil S
Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
[TBL] [Abstract][Full Text] [Related]
19. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
[TBL] [Abstract][Full Text] [Related]
20. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
